Projenx
UEI: TJLMX6EDJ8W9
• CAGE: 9Y6A4
Overview
Awardee Type
Parent
Company Description
ProJenX's mission is to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.
Name
Projenx
Website
Headquarters
New York, NY
United States
United States
Most Recent Award
April 1, 2025
Calculating
Federal grant recipient
PROJENX INC
(UEI TJLMX6EDJ8W9, CAGE 9Y6A4)
is headquartered in New York NY.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in August 2021 and
federally registered in
July 2024.
Federal Award Analysis
Projenx federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
PROJENX INC
UEI
TJLMX6EDJ8W9
CAGE Code
9Y6A4
SBA Certifications
None
Self Certifications
Self-Certified Small Disadvantaged Business
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Aug. 23, 2021
Initial Registration
July 1, 2024
Last Registration
July 9, 2024
Registration Activation
July 3, 2024
Registration Expiration
July 1, 2025
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Accepts Credit Cards
Yes